Cargando…
In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B
The cytochrome P450-mediated Phase I in vitro metabolism of CRV431 was studied using selective chemical inhibition and recombinant human enzymes. Additionally, the metabolic profile of CRV431 in human, rat, and monkey liver microsomes was investigated. Liver microsomes were incubated for 0–80 min wi...
Autores principales: | Trepanier, Daniel J., Ure, Daren R., Foster, Robert T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750657/ https://www.ncbi.nlm.nih.gov/pubmed/29120380 http://dx.doi.org/10.3390/pharmaceutics9040051 |
Ejemplares similares
-
The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
por: Gallay, Philippe, et al.
Publicado: (2019) -
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
por: Kuo, Joseph, et al.
Publicado: (2019) -
The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication
por: Foster, R.T., et al.
Publicado: (2017) -
Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice
por: Bobardt, Michael, et al.
Publicado: (2020) -
The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
por: Gallay, Philippe A., et al.
Publicado: (2015)